# BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging

> **NCT05552508** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 45 (actual)

## Conditions studied

- Asthma

## Interventions

- **COMBINATION_PRODUCT:** Benralizumab

## Key facts

- **NCT ID:** NCT05552508
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-11
- **Primary completion:** 2024-07-19
- **Final completion:** 2024-07-19
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05552508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05552508, "BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05552508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*